NOV 29, 2021 3:00 AM PST

An Amino Acid Can Improve Radiation Therapy for Metastatic Brain Cancer

WRITTEN BY: Katie Kokolus

There are 20 different amino acids that the human body uses to generate proteins.  Amino acids form chains called polypeptides which combine to form specific proteins required for biological functions.  Our genes contain the codes for the amino acid sequences which make up each protein.  

There are two types of amino acids: essential and non-essential.  While essential amino acids cannot be made by the body and must be consumed through the diet, the body produces non-essential amino acids. 

Arginine is one of the amino acids that the body makes on its own. It can also be consumed in high protein foods such as fish, read mead, poultry, whole grains, and dairy. The body converts arginine into a chemical called nitric oxide, which prompts blood vessels to widen or dilate. Doctors can prescribe arginine for some medical issues, including heart disease, because of its ability to work as a vasodilator. Supplemental arginine, commonly referred to as L-arginine, can be administered orally or even intravenously.  

A recent study published in Science Advances suggests a possible new indication for oral arginine in treating metastatic brain cancer.  Patients with metastatic brain cancer, a difficult to treat malignancy characterized by tumor cells spreading to the brain from a distant primary site.  Some brain metastases are inoperable, leading to the use of radiation therapy.  While radiation is effective in some cases, many tumors develop resistance, prompting the need to develop novel therapeutic options. 

Patients with metastatic brain cancer were randomized to treatment with either placebo (32 patients) or arginine treatment (31 patients) followed by whole-brain irradiation.  Participants in the treatment group received 10 grams of arginine one hour before each dose of radiation. 

The study demonstrated that pretreatment with arginine enhanced the efficacy of radiation therapy in patients with brain metastasis.  Only 3% of the participants receiving arginine experienced progressive disease.  Comparatively, 16% of those in the placebo group experienced disease progression.  Close to 80% of the arginine-treated group had a complete or partial response versus only 22% in the placebo group. 

Arginine is an affordable supplement associated with very few toxicities.  Thus, the promising results of this trial suggest that arginine could serve as a safe and inexpensive way to enhance the therapeutic benefit of radiation therapy.    

 

Sources: amino acids, polypeptides, Arginine, vasodilator, Science Advances

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
OCT 11, 2021
Cancer
Different Cancer Types Metastasize to Specific Regions of the Brain
OCT 11, 2021
Different Cancer Types Metastasize to Specific Regions of the Brain
Metastatic cancer occurs when cancer spreads from its original site of origin to a distant location in the body. Wh ...
OCT 12, 2021
Immunology
Cancer Drug Helps Alzheimer's Mice Remember
OCT 12, 2021
Cancer Drug Helps Alzheimer's Mice Remember
What if a drug—specifically developed to treat one disease—had the potential to address other non-related co ...
OCT 25, 2021
Cell & Molecular Biology
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
OCT 25, 2021
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
Labroots virtual events are a great place to share research and learn about others work. These events feature participan ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
DEC 19, 2021
Cancer
An Antibody to Clear the Way for Drug Delivery to Tumors
DEC 19, 2021
An Antibody to Clear the Way for Drug Delivery to Tumors
Tumors require blood vessels to obtain nutrients and growth factors needed for their expansion.  Many tumors effici ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
Loading Comments...